WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H599014
CAS#: 488127-53-3 (lithium)
Description: Topiramate lithium is a broad-spectrum anticonvulsant (antiepilepsy) drug. In late 2012, topiramate was approved by the United States Food and Drug Administration (FDA) in combination with phentermine for weight loss.
Hodoodo Cat#: H599014
Name: Topiramate lithium
CAS#: 488127-53-3 (lithium)
Chemical Formula: C12H20LiNO8S
Exact Mass: 0.00
Molecular Weight: 345.290
Elemental Analysis: C, 41.74; H, 5.84; Li, 2.01; N, 4.06; O, 37.07; S, 9.28
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 488127-53-3 (lithium) 97240-79-4 (free base)
Synonym: Topiramate lithium; Lithium topiramate;
IUPAC/Chemical Name: lithium ((((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methoxy)sulfonyl)amide
InChi Key: FRVIGWXXRZKZOL-WGAVTJJLSA-N
InChi Code: InChI=1S/C12H20NO8S.Li/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12;/h7-9H,5-6H2,1-4H3,(H-,13,14,15);/q-1;+1/t7-,8-,9+,12+;/m1./s1
SMILES Code: CC1(O[C@H]([C@@H](CO[C@@]2(COS(=O)([NH-])=O)O3)O1)[C@@H]2OC3(C)C)C.[Li+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 345.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Mirsepassi Z, Mazinani R, Fadai F, Alibeigi N, Nazeri Astaneh A. Topiramate Add-on Lithium Carbonate for Treatment of Acute Mania. Iran J Psychiatry Behav Sci. 2013 Fall;7(2):11-5. PubMed PMID: 24644505; PubMed Central PMCID: PMC3939989.
2: Sahraian A, Bigdeli M, Ghanizadeh A, Akhondzadeh S. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial. J Affect Disord. 2014 Sep;166:201-5. doi: 10.1016/j.jad.2014.05.015. Epub 2014 May 24. PubMed PMID: 25012432.
3: Pigott K, Galizia I, Vasudev K, Watson S, Geddes J, Young AH. Topiramate for acute affective episodes in bipolar disorder in adults. Cochrane Database Syst Rev. 2016 Sep 3;9:CD003384. doi: 10.1002/14651858.CD003384.pub3. Review. PubMed PMID: 27591453.
4: Mahmoudi-Gharaei J, Shahrivar Z, Faghihi T, Mohammadi MR, Tehrani-Doost M, Alaghband-Rad J, Ghaeli P. Topiramate versus Valproate Sodium as Adjunctive Therapies to a Combination of Lithium and Risperidone for Adolescents with Bipolar I Disorder: Effects on Weight and Serum Lipid Profiles. Iran J Psychiatry. 2012 Winter;7(1):1-10. PubMed PMID: 23056111; PubMed Central PMCID: PMC3395968.
5: Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci. 2014 Jun 18;5(6):459-67. doi: 10.1021/cn500058v. Epub 2014 May 15. Review. PubMed PMID: 24786695; PubMed Central PMCID: PMC4063504.
6: Kotwal R, Guerdjikova A, McElroy SL, Keck PE Jr. Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity. Hum Psychopharmacol. 2006 Oct;21(7):425-31. PubMed PMID: 16941522.
7: Álvarez Ruiz EM, Gutiérrez-Rojas L. Comorbidity of bipolar disorder and eating disorders. Rev Psiquiatr Salud Ment. 2015 Oct-Dec;8(4):232-41. doi: 10.1016/j.rpsm.2014.12.001. Epub 2015 Mar 3. Review. English, Spanish. PubMed PMID: 25745820.
8: Rigoulot MA, Koning E, Ferrandon A, Nehlig A. Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. J Pharmacol Exp Ther. 2004 Feb;308(2):787-95. Epub 2003 Oct 30. PubMed PMID: 14593082.
9: Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther. 2002 Oct;24(10):1576-84. PubMed PMID: 12462287.
10: Nicolato R, Romano-Silva MA, Correa H, Salgado JV, Teixeira AL. Lithium and topiramate association in the treatment of comorbid pathological gambling and bipolar disorder. Aust N Z J Psychiatry. 2007 Jul;41(7):628. PubMed PMID: 17558627.
11: Abraham G, Owen J. Topiramate can cause lithium toxicity. J Clin Psychopharmacol. 2004 Oct;24(5):565-7. PubMed PMID: 15349023.
12: Mathew T, Sarma GR, Nadig R, Varghese R. Topiramate-induced somnambulism in a migraineur: a probable idiosyncratic adverse effect. J Clin Sleep Med. 2012 Apr 15;8(2):197-8. doi: 10.5664/jcsm.1782. PubMed PMID: 22505867; PubMed Central PMCID: PMC3311419.
13: Pinninti NR, Zelinski G. Does topiramate elevate serum lithium levels? J Clin Psychopharmacol. 2002 Jun;22(3):340. PubMed PMID: 12006910.
14: Comai S, Tau M, Pavlovic Z, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharmacol. 2012 Apr;32(2):237-60. doi: 10.1097/JCP.0b013e31824929d6. Review. PubMed PMID: 22367663.
15: Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43(12):763-80. Review. PubMed PMID: 15355124.
16: Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs. 2010 Jun;24(6):501-26. doi: 10.2165/11533180-000000000-00000. Review. PubMed PMID: 20443647.
17: Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011 Oct 8;378(9799):1306-15. doi: 10.1016/S0140-6736(11)60873-8. Epub 2011 Aug 16. Review. PubMed PMID: 21851976.
18: Maksimovic M, Vekovischeva OY, Aitta-aho T, Korpi ER. Chronic treatment with mood-stabilizers attenuates abnormal hyperlocomotion of GluA1-subunit deficient mice. PLoS One. 2014 Jun 16;9(6):e100188. doi: 10.1371/journal.pone.0100188. eCollection 2014. PubMed PMID: 24932798; PubMed Central PMCID: PMC4059755.
19: Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord. 2001 Oct;3(5):215-32. Review. PubMed PMID: 11912568.
20: François J, Koning E, Ferrandon A, Nehlig A. The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res. 2006 Dec;72(2-3):147-63. Epub 2006 Sep 1. PubMed PMID: 16945504.
